Abstract 686TiP
Background
ZG006 is a trispecific anti-T cell engager (Tri-TE) targeting Delta-like ligand 3 (DLL3) and CD3, designed to bridge tumor cells and T cells by binding to two distinct DLL3 epitopes on tumor cells and CD3 on T cells, thereby mediating tumor-infiltrating T cell-specific killing of DLL3-expressing tumor cells such as small cell lung cancer and neuroendocrine carcinomas. Based on its molecular structure, ZG006 may have excellent cytotoxic effects against tumors with low DLL3 expression. Preclinical pharmacological and toxicological studies have demonstrated that ZG006 exhibits promising anti-tumor activity and favorable safety profiles both in vitro and in vivo. We have conducted a Phase I clinical study to assess the tolerability, safety, preliminary efficacy of ZG006.
Trial design
This is a multi-center, open-label, Phase I clinical study of ZG006 for the treatment of subjects with advanced small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment. During the dose escalation stage, an accelerated titration design (ATD) combined with the standard “3+3” design will be used to assess the Recommended Phase 2 Dose (RP2D) for the subsequent studies. Therefore, the dose groups of ZG006 for dose escalations are set as 0.1 mg, 0.3 mg, 1 mg, 3 mg, 10 mg and 30 mg, intravenous administration, once every two weeks. The first 28-day-period was defined as the dose-limiting toxicity (DLT) observation period. After the completion of the DLT observation period, subjects can continue to receive ZG006 treatment until the occurrence of intolerable toxicity, disease progression, initiation of new anti-tumor therapy, withdrawal of consent (whichever comes first). Imaging efficacy assessments are conducted every 6 weeks within 48 weeks post-initial dosing, followed by assessments every 12 weeks thereafter. Tumor response was assessed by RECIST1.1. Pharmacokinetics and DLL3 expressions were also assessed in this study.
Clinical trial identification
NCT05978284.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Suzhou Zelgen BioPharmaceuticals. Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01